Exhibitors Search
RNAGENE Inc.
| Exhibition | NextRegenX |
|---|---|
| Booth no. | B36 |
| Country | Korea, South |
| Address | 7 Beobwon-ro 6-gil, Songpa-gu, Seoul, Republic of Korea |
| Tel (Rep.) | 02-407-0331 |
| Website | http://www.RNAGENE.com |
Company Introduction
Company: RNAGENE Inc.
Main Business
- Development of mRNA vaccines for COVID-19 and seasonal influenza (government-supported)
- Customized mRNA synthesis and sequence provision to 30+ research institutions
Core Platforms
- OUSPERA: mRNA structure design platform
- TARSPED: Tissue-specific LNP delivery platform
- TAPTOD: Immune cell activation platform
Technology Strengths
- Precise drug delivery system via peptide-mediated ligand/antibody conjugation
- Applicable to gene editing and nucleic acid-based therapeutics
Vision
- To accelerate research with high-quality mRNA synthesis services
- To lead innovation in the era of mRNA medicines, including cancer vaccines and rare disease treatments
Main Business
- Development of mRNA vaccines for COVID-19 and seasonal influenza (government-supported)
- Customized mRNA synthesis and sequence provision to 30+ research institutions
Core Platforms
- OUSPERA: mRNA structure design platform
- TARSPED: Tissue-specific LNP delivery platform
- TAPTOD: Immune cell activation platform
Technology Strengths
- Precise drug delivery system via peptide-mediated ligand/antibody conjugation
- Applicable to gene editing and nucleic acid-based therapeutics
Vision
- To accelerate research with high-quality mRNA synthesis services
- To lead innovation in the era of mRNA medicines, including cancer vaccines and rare disease treatments
Promotional video
Exhibit Item
Custom mRNA synthesis (research to preclinical scale) High-purity, high-efficiency IVT process with capping & poly(A) tailing Sequence design and optimization consulting LNP formulation and in vitro/in vivo delivery evaluation Strengths: fast turnaround, flexible conditions, global-standard quality assurance
Exhibit Description
Custom mRNA synthesis for research and preclinical use
High-purity IVT process with capping & poly(A) tailing
LNP formulation and in vitro/in vivo delivery evaluation
Fast turnaround and flexible, researcher-tailored conditions
High-purity IVT process with capping & poly(A) tailing
LNP formulation and in vitro/in vivo delivery evaluation
Fast turnaround and flexible, researcher-tailored conditions
Co-Exhibitor or Partner’s Information
| Company Name | Country |
|---|---|
KYUNGYON EXHIBITION CORP.